New inhaled therapy tested to slow scarring of the lungs
Disease control
Not yet recruiting
This study is testing whether inhaling a drug called nintedanib (AP02) can help slow down lung scarring in people with Idiopathic Pulmonary Fibrosis (IPF). About 160 adults with IPF will be randomly assigned to receive one of two doses of the inhaled drug or a placebo (an inactiv…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC